CD BioGlyco has rich experience in producing human milk oligosaccharides (HMOs) according to our clients' detailed requirements. We have diverse Technologies for HMO Production. We have the confidence to customize the best solution to help you resolve problems.
Human milk is an abundant source of various carbohydrates. There are about 80-90 HMOs have been isolated from bread milk and sequences assigned. Plenty of oligosaccharides’ structures, closely relating to the Carbohydrate chains of Glycoproteins and Glycolipids, are meaningful for many biological studies. It is important for HMOs to inhibit bacterial adhesion to epithelial surfaces. Because HMOs mimic the binding epitope of the epithelial receptor. It is well-known that the infection of numerous bacteria as well as viruses starts by combining with special carbohydrate chains of glycoconjugates on the surface of cells, which constitute the mucous epithelium of digestive tracts and respiratory tracts. Consequently, HMOs might contribute to elucidating the structures of the target sugar chain of each bacterium or virus on the surface of epithelial cells.
Neutral non-fucosylated oligosaccharides are the crucial framework of all HMOs. LNnD belongs to neutral non-fucosylated oligosaccharides in breast milk. The core structure of LNnD is shown in Fig.1.
Fig.1 Core structure of LNnD. (CD BioGlyco)
CD BioGlyco has enzymatic, chemoenzymatic, whole-cell, and living-cell approaches which produce HMOs by recombinant bacterial glycosyltransferases. Because bacteria express a series of glycosyltransferases that are able to construct various structures of lipopolysaccharides (LPS) and capsular polysaccharides. Some of these glycan structures are similar to those found on human cell surfaces and those in HMOs. Consequently, CD BioGlyco uses bacteria, an abundant source of glycosyltransferases, for the production of HMOs as well as the glycans and glycoconjugates presented on the surface of human cells. We provide LNnD production services of high quality by enzyme-catalyzed processes. LNnD is produced by using living E. coli JM109 cells (lacY+ lacZ-) engineered to overexpress Neisseria meningitides β1-3-N-acetylglucosaminyltransferase (NmLgtA) and Neisseria meningitides β1–4GalT (NmLgtB) at CD BioGlyco. The products we produce will be identified by high performance liquid chromatography-mass spectrometry (HPLC-MS) to determine high-purity and high-quality HMOs.
CD BioGlyco is a biotechnology company with professional services. We have the best team of experts in the world at your service. Customers can contact our employees directly and we will reply quickly. If you are interested in our services, please feel free to contact us for more detailed information.
Reference
